MedTrace Logo

Cannabidiol Oil Extract for Prevention of Postoperative Nausea and Vomiting

NCT06137027 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2023-11-18

No results posted yet for this study

Summary

Cannabidiol oil has been shown to be effective in treating chemotherapy induced nausea and vomiting, but there is limited information on its usefulness in nausea and vomiting that can occur after surgery. The goal of this study is to determine the effect of Cannabidiol oil on the frequency of nausea and vomiting in the first 24 hours after a gynaecological procedure. Other effects that will be assessed will include:

1. The effect of Cannabidiol oil on the level of pain and amount of pain medications needed in the first 24 hours after a gynaecological operation.
2. The effect of Cannabidiol oil on patients' overall satisfaction with the anaesthetic experience.

Some participants will be administered Cannabidiol oil under the tongue two to three hours before their procedure and an equal number will receive a placebo oil, similar in taste. This will be done randomly to minimise introducing bias. We will then compare both groups in the postoperative period to see if the Cannabidiol oil made any difference.

Conditions

  • Postoperative Nausea and Vomiting

Interventions

DRUG

Cannabidiol Oil

Cannabidiol oil will be administered sublingually 2-3 hours preoperatively

DRUG

Placebo

Placebo will be administered sublingually 2-3 hours preoperatively

Sponsors & Collaborators

  • The University of The West Indies

    lead OTHER

Principal Investigators

  • Ingrid Tennant, DM, PhD · University Hospital of the West Indies

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-21
Primary Completion
2024-01-31
Completion
2024-02-29

Countries

  • Jamaica

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06137027 on ClinicalTrials.gov